Journal Options Oncology: Hematologic Malignancies, Volume 2, Issue 1

Course Director: Robert S. Mocharnuk, MD

Faculty:

Bruce D. Cheson, MD Bruce Dezube, MD Frederick B. Hagemeister, MD

Sagar Lonial, MD Craig H. Moskowitz, MD Liron Pantanowitz, MD

Noopur Raje, MD Deborah A. Thomas, MD Steven P. Treon, MD, MA, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss recently published findings regarding the pathogenesis and natural history of hematologic malignancies
• Summarize recent findings on the diagnosis, treatment, and prevention of hematologic malignancies
• Analyze clinical trials of new agents and diagnostic methods and their impact on patient care

Topics covered include:

• Maintenance Therapy With Thalidomide in Patients With Multiple Myeloma
• Lenalidomide Shows High Response Rate in Patients With Relapsed or Refractory B-Cell CLL
• Bortezomib in the Treatment of Patients With Waldenström’s Macroglobulinemia
• Rituximab Maintenance Therapy After R-FCM in Patients With Recurrent/Refractory Follicular and Mantle Cell Lymphomas
• Bortezomib Plus Dexamethasone as Induction Treatment Before Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma 
• Magnetic Resonance Imaging vs Metastatic Bone Survey for the Detection of Focal Lesions in Patients With Multiple Myeloma
• ABVD and HAART in Advanced-Stage HIV-Related Hodgkin’s Disease 
• The Significance of Complete Responses After Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Non-Hodgkin’s Lymphoma 
• Karyotype Complexity Is a Prognostic Factor in Adult Acute Lymphoblastic Leukemia: ECOG 2993 Trial Analysis 
• Addition of Oblimersen to Fludarabine Plus Cyclophosphamide Increases Response Rate and Duration of Response in Patients With Relapsed or Refractory CLL